{"id":6499,"date":"2007-12-14T13:16:00","date_gmt":"2007-12-14T13:16:00","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&p=6499"},"modified":"2021-12-14T13:18:49","modified_gmt":"2021-12-14T13:18:49","slug":"a-case-report-of-steroid-and-immunosuppressant-resistant-pyoderma-gangrenosum-successfully-treated-by-granulocytapheresis-2","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/fr\/professional\/scientific-corner\/a-case-report-of-steroid-and-immunosuppressant-resistant-pyoderma-gangrenosum-successfully-treated-by-granulocytapheresis-2\/","title":{"rendered":"A Case Report of Steroid and Immunosuppressant-resistant Pyoderma Gangrenosum Successfully Treated by Granulocytapheresis"},"content":{"rendered":"
\n

Keiko Okuma<\/a>,Kouichi Mitsuishi<\/a>,Toshio Hasegawa<\/a>,Hitoshi Tsuchihashi<\/a>,Hideoki Ogawa<\/a>,Shigaku Ikeda<\/a>, <\/p>\n<\/div>\n\n

\n

https:\/\/doi.org\/10.1111\/j.1744-9987.2007.00498.x<\/a><\/p>\n<\/div>\n\n

\n

Abstract:\u00a0<\/strong>Granulocytapheresis (GCAP) therapy is a newly developed therapeutic modality for inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease. Pyoderma gangrenosum (PG) is a chronic inflammatory skin disease characterized by the appearance of erythematous macules and plaques with pustules or nodules that rapidly progress to ragged, undermined multiple ulcers. We attempted GCAP therapy in a patient with PG resistant to prednisolone and various other immunosuppressants. GCAP therapy was initiated at three- to four-day intervals and a good response from all skin lesions, with eventual total epithelialization, was observed after 10 sessions of this therapy. Furthermore, circulating levels of inflammatory cytokines such as interleukin-8 (IL-8) and granulocyte colony stimulating factor (G-CSF) also decreased after the GCAP therapy. Our results suggest that GCAP is a safe and useful tool for the treatment of intractable PG, and that IL-8 and G-CSF are likely to be involved in the pathogenesis of PG.<\/p>\n<\/div>\n\n

\n

https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1744-9987.2007.00498.x<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Keiko Okuma,Kouichi Mitsuishi,Toshio Hasegawa,Hitoshi Tsuchihashi,Hideoki Ogawa,Shigaku Ikeda, https:\/\/doi.org\/10.1111\/j.1744-9987.2007.00498.x Abstract:\u00a0Granulocytapheresis (GCAP) therapy is a newly developed therapeutic modality for inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease. Pyoderma gangrenosum (PG) is a chronic inflammatory skin disease characterized by the appearance of erythematous macules and plaques with pustules or nodules that rapidly progress to ragged, […]<\/p>\n","protected":false},"template":"","scientific_tags":[424,385,212,47,115,280],"class_list":["post-6499","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-gma","scientific_tags-granulocytapheresis","scientific_tags-immunosuppressant-resistant","scientific_tags-prednisolone","scientific_tags-pyoderma-gangrenosum","scientific_tags-steroids"],"acf":{"sc_authors":""},"yoast_head":"\nA Case Report of Steroid and Immunosuppressant-resistant Pyoderma Gangrenosum Successfully Treated by Granulocytapheresis - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/a-case-report-of-steroid-and-immunosuppressant-resistant-pyoderma-gangrenosum-successfully-treated-by-granulocytapheresis-2\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"A Case Report of Steroid and Immunosuppressant-resistant Pyoderma Gangrenosum Successfully Treated by Granulocytapheresis - Adacyte\" \/>\n<meta property=\"og:description\" content=\"Keiko Okuma,Kouichi Mitsuishi,Toshio Hasegawa,Hitoshi Tsuchihashi,Hideoki Ogawa,Shigaku Ikeda, https:\/\/doi.org\/10.1111\/j.1744-9987.2007.00498.x Abstract:\u00a0Granulocytapheresis (GCAP) therapy is a newly developed therapeutic modality for inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease. Pyoderma gangrenosum (PG) is a chronic inflammatory skin disease characterized by the appearance of erythematous macules and plaques with pustules or nodules that rapidly progress to ragged, […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/a-case-report-of-steroid-and-immunosuppressant-resistant-pyoderma-gangrenosum-successfully-treated-by-granulocytapheresis-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2021-12-14T13:18:49+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/a-case-report-of-steroid-and-immunosuppressant-resistant-pyoderma-gangrenosum-successfully-treated-by-granulocytapheresis-2\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/a-case-report-of-steroid-and-immunosuppressant-resistant-pyoderma-gangrenosum-successfully-treated-by-granulocytapheresis-2\/\",\"name\":\"A Case Report of Steroid and Immunosuppressant-resistant Pyoderma Gangrenosum Successfully Treated by Granulocytapheresis - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2007-12-14T13:16:00+00:00\",\"dateModified\":\"2021-12-14T13:18:49+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/a-case-report-of-steroid-and-immunosuppressant-resistant-pyoderma-gangrenosum-successfully-treated-by-granulocytapheresis-2\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"A Case Report of Steroid and Immunosuppressant-resistant Pyoderma Gangrenosum Successfully Treated by Granulocytapheresis - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/a-case-report-of-steroid-and-immunosuppressant-resistant-pyoderma-gangrenosum-successfully-treated-by-granulocytapheresis-2\/","og_locale":"fr_FR","og_type":"article","og_title":"A Case Report of Steroid and Immunosuppressant-resistant Pyoderma Gangrenosum Successfully Treated by Granulocytapheresis - Adacyte","og_description":"Keiko Okuma,Kouichi Mitsuishi,Toshio Hasegawa,Hitoshi Tsuchihashi,Hideoki Ogawa,Shigaku Ikeda, https:\/\/doi.org\/10.1111\/j.1744-9987.2007.00498.x Abstract:\u00a0Granulocytapheresis (GCAP) therapy is a newly developed therapeutic modality for inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease. Pyoderma gangrenosum (PG) is a chronic inflammatory skin disease characterized by the appearance of erythematous macules and plaques with pustules or nodules that rapidly progress to ragged, […]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/a-case-report-of-steroid-and-immunosuppressant-resistant-pyoderma-gangrenosum-successfully-treated-by-granulocytapheresis-2\/","og_site_name":"Adacyte","article_modified_time":"2021-12-14T13:18:49+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/a-case-report-of-steroid-and-immunosuppressant-resistant-pyoderma-gangrenosum-successfully-treated-by-granulocytapheresis-2\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/a-case-report-of-steroid-and-immunosuppressant-resistant-pyoderma-gangrenosum-successfully-treated-by-granulocytapheresis-2\/","name":"A Case Report of Steroid and Immunosuppressant-resistant Pyoderma Gangrenosum Successfully Treated by Granulocytapheresis - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2007-12-14T13:16:00+00:00","dateModified":"2021-12-14T13:18:49+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/a-case-report-of-steroid-and-immunosuppressant-resistant-pyoderma-gangrenosum-successfully-treated-by-granulocytapheresis-2\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific-corner\/6499","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/media?parent=6499"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific_tags?post=6499"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}